Related Experiment Video

Updated: Apr 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up

Gabriel Anabwani1, Christoph Königs2, Carlos Giaquinto3

  • 1Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|April 29, 2015
PubMed

Insights

Extended-release nevirapine proved safe and effective for children and adolescents with human immunodeficiency virus (HIV) over 48 weeks. All participants achieved undetectable viral loads, showing the benefit of this once-daily antiretroviral therapy.

Area of Science:

  • Pediatric infectious diseases
  • Antiretroviral therapy research
  • Virology

Background:

  • Human immunodeficiency virus (HIV) infection in pediatric populations requires effective and safe long-term treatment options.
  • Extended-release nevirapine is an antiretroviral medication used in HIV management.

Purpose of the Study:

  • To evaluate the long-term safety and efficacy of extended-release nevirapine in pediatric patients with HIV.
  • To assess the durability of viral load suppression with a once-daily antiretroviral regimen in this population.

Main Methods:

  • An optional extension of clinical trial 1100.1518 was conducted.
  • Pediatric patients (3 to <18 years) with HIV received extended-release nevirapine for at least 48 weeks.
  • Viral load and safety data were monitored throughout the treatment period.

Main Results:

  • All patients achieved undetectable viral loads by their last visit.
  • No new safety signals were identified during the extended treatment period.
  • The once-daily extended-release nevirapine regimen demonstrated sustained efficacy and a favorable safety profile.

Conclusions:

  • Extended-release nevirapine is a safe and effective option for long-term HIV treatment in children and adolescents.
  • A once-daily antiretroviral regimen can achieve and maintain undetectable viral loads in pediatric HIV patients.
  • The study supports the use of extended-release nevirapine for sustained viral suppression and safety in pediatric HIV management.

Keywords:
HIV-1extended-release formulationlong-term follow-upnevirapinepediatric patients

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.6K
Humanized NOD/SCID/IL2r&#947;null (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
389
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
499
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
829
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
354
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
16.0K